Active Stocks
Mon Apr 22 2024 12:36:58
  1. Tata Steel share price
  2. 162.65 0.34%
  1. HDFC Bank share price
  2. 1,518.90 -0.81%
  1. Wipro share price
  2. 462.15 2.05%
  1. NTPC share price
  2. 345.30 -1.60%
  1. Tata Motors share price
  2. 971.30 0.84%
Business News/ Markets / Mark To Market/  Glenmark Pharma: Decent Q2 may signal a reversal; capital infusion key
BackBack

Glenmark Pharma: Decent Q2 may signal a reversal; capital infusion key

Glenmark’s domestic business grew about 15% year-on-year in Q2FY20
  • Ebitda margins is 200 bps more than analysts’ estimate. This is despite higher expenses due to rising staff costs
  • A ramp-up in the distribution of some of its new launches drove US markets.Premium
    A ramp-up in the distribution of some of its new launches drove US markets.

    After a scare in the first quarter, Glenmark Pharmaceuticals Ltd has been recuperating quite nicely. The company delivered a strong quarterly performance ahead of the Street’s expectations. Growth in two of its key markets, India and the US, pushed revenue and operating metrics higher. Shares of Glenmark, which were hovering at their 52-week lows, pulled back sharply and gained 22% on Monday.

    Glenmark’s domestic business grew by about 15% year-on-year in Q2 FY20, which is decent. The firm gained market share in some key therapies domestically. Besides, the US business grew marginally from a year ago, but quarter-on-quarter growth stood at 14%. This beats the Street’s estimates by 12-13%.


    Given that the US market is facing high competitive pricing pressure, the recovery is a positive sign. Further, the commentary from the management has been cautiously optimistic, with growth rates expected to be in mid-single digits in the second half. The company is expecting approval for two products in the US, which will further aid growth rates. Additionally, the rest of the world business is also gaining momentum.

    As a result of the improvement in revenue growth, Ebitda (earnings before interest, tax, depreciation and amortization) margins have expanded. In fact, Ebitda margins of 16% this quarter is about 200 basis points higher than analysts’ expectation of about 14%. This is despite higher expenses due to rising staff costs.

    Net debt, which increased marginally in Q2, however still remains a concern. “However, we are yet to see any net debt reduction, net debt increased by US$10mn in 1HFY20, from the core business (capital expenditures at US$ 100 mn+ and R&D at US$185 mn—both continue to be high). The management expects debt reduction to be achieved from the divestment of non-core assets where they expect some closure of deal over the next two quarters," said Credit Suisse India in a note to clients.

    The company has hived off its innovative research and development division into a separate firm, Ichnos Sciences. Glenmark is looking for equity funds for this business. “Operationally, the company has done well in the second quarter. But fund-raising has become critical because it needs capital to support research and also to cut back on debt. If that happens by the year-end, it will be a major improvement," said Bhavesh Gandhi, senior analyst (institutional equities) at Yes Securities Ltd.

    Analysts expect Glenmark’s net debt to shrink by about $3 billion by the end of this year, which will reduce its debt-equity ratio. Meanwhile, the stock’s recovery has come on the back of a steep fall over the past year. Further recovery will depend on how quickly Glenmark can get the required capital.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 18 Nov 2019, 10:56 AM IST
    Next Story footLogo
    Recommended For You
    GENIE RECOMMENDS

    Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

    Let’s get started
    Switch to the Mint app for fast and personalized news - Get App